Enlicitide chloride
Appearance
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C82H110ClFN14O15 |
Molar mass | 1586.31 g·mol−1 |
3D model (JSmol) | |
| |
|
Enlicitide chloride (INN;[1] previously known as MK-0616) is a macrocyclic peptide investigational drug who is being evaluated for the treatment of hypercholesterolaemia. It is a PCSK9 inhibitor.[2]
References
- ^ "Recommended International Nonproprietary Names: List 90" (PDF). WHO Drug Information. 37 (3): 753–754. ISBN 978-92-4-008139-0.
- ^ Burnett JR, Hooper AJ (2023). "MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment". Expert Opinion on Investigational Drugs. 32 (10): 873–878. doi:10.1080/13543784.2023.2267972. PMID 37815341. S2CID 263802012.